Cargando…

Clinical features and outcomes of combined hepatocellular carcinoma and cholangiocarcinoma versus hepatocellular carcinoma versus cholangiocarcinoma after surgical resection: a propensity score matching analysis

BACKGROUND: Combined hepatocellular carcinoma and cholangiocarcinoma (cHCC-CC) is an infrequent type of primary liver cancer that comprises hepatocellular carcinoma (HCC) and cholangiocarcinoma (CC). This study investigated the clinicopathological features and prognosis among cHCC-CC, HCC, and CC gr...

Descripción completa

Detalles Bibliográficos
Autores principales: Lin, Chih-Wen, Wu, Tsung-Chin, Lin, Hung-Yu, Hung, Chao-Ming, Hsieh, Pei-Min, Yeh, Jen-Hao, Hsiao, Pojen, Huang, Ya-Ling, Li, Yu-Chan, Wang, Ya-Chin, Shu, Chih-Wen, Chen, Yaw-Sen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7788698/
https://www.ncbi.nlm.nih.gov/pubmed/33413162
http://dx.doi.org/10.1186/s12876-020-01586-4
_version_ 1783633080221696000
author Lin, Chih-Wen
Wu, Tsung-Chin
Lin, Hung-Yu
Hung, Chao-Ming
Hsieh, Pei-Min
Yeh, Jen-Hao
Hsiao, Pojen
Huang, Ya-Ling
Li, Yu-Chan
Wang, Ya-Chin
Shu, Chih-Wen
Chen, Yaw-Sen
author_facet Lin, Chih-Wen
Wu, Tsung-Chin
Lin, Hung-Yu
Hung, Chao-Ming
Hsieh, Pei-Min
Yeh, Jen-Hao
Hsiao, Pojen
Huang, Ya-Ling
Li, Yu-Chan
Wang, Ya-Chin
Shu, Chih-Wen
Chen, Yaw-Sen
author_sort Lin, Chih-Wen
collection PubMed
description BACKGROUND: Combined hepatocellular carcinoma and cholangiocarcinoma (cHCC-CC) is an infrequent type of primary liver cancer that comprises hepatocellular carcinoma (HCC) and cholangiocarcinoma (CC). This study investigated the clinicopathological features and prognosis among cHCC-CC, HCC, and CC groups. METHODS: We prospectively collected the data of 608 patients who underwent surgical resection for liver cancer between 2011 and 2018 at E-Da Hospital, I-Shou University, Kaohsiung, Taiwan. Overall, 505 patients with cHCC-CC, HCC, and CC were included, and their clinicopathological features, overall survival (OS), and recurrence were recorded. OS and recurrence rates were analyzed using the Kaplan–Meier analysis. RESULTS: In the entire cohort, the median age was 61 years and 80% were men. Thirty-five (7.0%) had cHCC-CC, 419 (82.9%) had HCC, and 51 (10.1%) had CC. The clinicopathological features of the cHCC-CC group were more identical to those of the HCC group than the CC group. OS was significantly lower in the cHCC-CC group than in the HCC group but was not significantly higher in the cHCC-CC group than in the CC group. The median OS of cHCC-CC, HCC, and CC groups was 50.1 months [95% confidence interval (CI): 38.7–61.2], 62.3 months (CI: 42.1–72.9), and 36.2 months (CI: 15.4–56.5), respectively. Cumulative OS rates at 1, 3, and 5 years in cHCC-CC, HCC, and CC groups were 88.5%, 62.2%, and 44.0%; 91.2%, 76.1%, and 68.0%; and 72.0%, 48.1%, and 34.5%, respectively. After propensity score matching (PSM), OS in the cHCC-CC group was not significantly different from that in the HCC or CC group. However, OS was significantly higher in the HCC group than in the CC group before and after PSM. Furthermore, the disease-free survival was not significantly different among cHCC-CC, HCC, and CC groups before and after PSM. CONCLUSION: The clinicopathological features of the cHCC-CC group were more identical to those of the HCC group than the CC group. The OS rate was significantly lower in the cHCC-CC group than the HCC group. However, after PSM, OS and disease-free survival in the cHCC-CC group were not significantly different from those in the HCC or CC group.
format Online
Article
Text
id pubmed-7788698
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-77886982021-01-07 Clinical features and outcomes of combined hepatocellular carcinoma and cholangiocarcinoma versus hepatocellular carcinoma versus cholangiocarcinoma after surgical resection: a propensity score matching analysis Lin, Chih-Wen Wu, Tsung-Chin Lin, Hung-Yu Hung, Chao-Ming Hsieh, Pei-Min Yeh, Jen-Hao Hsiao, Pojen Huang, Ya-Ling Li, Yu-Chan Wang, Ya-Chin Shu, Chih-Wen Chen, Yaw-Sen BMC Gastroenterol Research Article BACKGROUND: Combined hepatocellular carcinoma and cholangiocarcinoma (cHCC-CC) is an infrequent type of primary liver cancer that comprises hepatocellular carcinoma (HCC) and cholangiocarcinoma (CC). This study investigated the clinicopathological features and prognosis among cHCC-CC, HCC, and CC groups. METHODS: We prospectively collected the data of 608 patients who underwent surgical resection for liver cancer between 2011 and 2018 at E-Da Hospital, I-Shou University, Kaohsiung, Taiwan. Overall, 505 patients with cHCC-CC, HCC, and CC were included, and their clinicopathological features, overall survival (OS), and recurrence were recorded. OS and recurrence rates were analyzed using the Kaplan–Meier analysis. RESULTS: In the entire cohort, the median age was 61 years and 80% were men. Thirty-five (7.0%) had cHCC-CC, 419 (82.9%) had HCC, and 51 (10.1%) had CC. The clinicopathological features of the cHCC-CC group were more identical to those of the HCC group than the CC group. OS was significantly lower in the cHCC-CC group than in the HCC group but was not significantly higher in the cHCC-CC group than in the CC group. The median OS of cHCC-CC, HCC, and CC groups was 50.1 months [95% confidence interval (CI): 38.7–61.2], 62.3 months (CI: 42.1–72.9), and 36.2 months (CI: 15.4–56.5), respectively. Cumulative OS rates at 1, 3, and 5 years in cHCC-CC, HCC, and CC groups were 88.5%, 62.2%, and 44.0%; 91.2%, 76.1%, and 68.0%; and 72.0%, 48.1%, and 34.5%, respectively. After propensity score matching (PSM), OS in the cHCC-CC group was not significantly different from that in the HCC or CC group. However, OS was significantly higher in the HCC group than in the CC group before and after PSM. Furthermore, the disease-free survival was not significantly different among cHCC-CC, HCC, and CC groups before and after PSM. CONCLUSION: The clinicopathological features of the cHCC-CC group were more identical to those of the HCC group than the CC group. The OS rate was significantly lower in the cHCC-CC group than the HCC group. However, after PSM, OS and disease-free survival in the cHCC-CC group were not significantly different from those in the HCC or CC group. BioMed Central 2021-01-07 /pmc/articles/PMC7788698/ /pubmed/33413162 http://dx.doi.org/10.1186/s12876-020-01586-4 Text en © The Author(s) 2021 Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research Article
Lin, Chih-Wen
Wu, Tsung-Chin
Lin, Hung-Yu
Hung, Chao-Ming
Hsieh, Pei-Min
Yeh, Jen-Hao
Hsiao, Pojen
Huang, Ya-Ling
Li, Yu-Chan
Wang, Ya-Chin
Shu, Chih-Wen
Chen, Yaw-Sen
Clinical features and outcomes of combined hepatocellular carcinoma and cholangiocarcinoma versus hepatocellular carcinoma versus cholangiocarcinoma after surgical resection: a propensity score matching analysis
title Clinical features and outcomes of combined hepatocellular carcinoma and cholangiocarcinoma versus hepatocellular carcinoma versus cholangiocarcinoma after surgical resection: a propensity score matching analysis
title_full Clinical features and outcomes of combined hepatocellular carcinoma and cholangiocarcinoma versus hepatocellular carcinoma versus cholangiocarcinoma after surgical resection: a propensity score matching analysis
title_fullStr Clinical features and outcomes of combined hepatocellular carcinoma and cholangiocarcinoma versus hepatocellular carcinoma versus cholangiocarcinoma after surgical resection: a propensity score matching analysis
title_full_unstemmed Clinical features and outcomes of combined hepatocellular carcinoma and cholangiocarcinoma versus hepatocellular carcinoma versus cholangiocarcinoma after surgical resection: a propensity score matching analysis
title_short Clinical features and outcomes of combined hepatocellular carcinoma and cholangiocarcinoma versus hepatocellular carcinoma versus cholangiocarcinoma after surgical resection: a propensity score matching analysis
title_sort clinical features and outcomes of combined hepatocellular carcinoma and cholangiocarcinoma versus hepatocellular carcinoma versus cholangiocarcinoma after surgical resection: a propensity score matching analysis
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7788698/
https://www.ncbi.nlm.nih.gov/pubmed/33413162
http://dx.doi.org/10.1186/s12876-020-01586-4
work_keys_str_mv AT linchihwen clinicalfeaturesandoutcomesofcombinedhepatocellularcarcinomaandcholangiocarcinomaversushepatocellularcarcinomaversuscholangiocarcinomaaftersurgicalresectionapropensityscorematchinganalysis
AT wutsungchin clinicalfeaturesandoutcomesofcombinedhepatocellularcarcinomaandcholangiocarcinomaversushepatocellularcarcinomaversuscholangiocarcinomaaftersurgicalresectionapropensityscorematchinganalysis
AT linhungyu clinicalfeaturesandoutcomesofcombinedhepatocellularcarcinomaandcholangiocarcinomaversushepatocellularcarcinomaversuscholangiocarcinomaaftersurgicalresectionapropensityscorematchinganalysis
AT hungchaoming clinicalfeaturesandoutcomesofcombinedhepatocellularcarcinomaandcholangiocarcinomaversushepatocellularcarcinomaversuscholangiocarcinomaaftersurgicalresectionapropensityscorematchinganalysis
AT hsiehpeimin clinicalfeaturesandoutcomesofcombinedhepatocellularcarcinomaandcholangiocarcinomaversushepatocellularcarcinomaversuscholangiocarcinomaaftersurgicalresectionapropensityscorematchinganalysis
AT yehjenhao clinicalfeaturesandoutcomesofcombinedhepatocellularcarcinomaandcholangiocarcinomaversushepatocellularcarcinomaversuscholangiocarcinomaaftersurgicalresectionapropensityscorematchinganalysis
AT hsiaopojen clinicalfeaturesandoutcomesofcombinedhepatocellularcarcinomaandcholangiocarcinomaversushepatocellularcarcinomaversuscholangiocarcinomaaftersurgicalresectionapropensityscorematchinganalysis
AT huangyaling clinicalfeaturesandoutcomesofcombinedhepatocellularcarcinomaandcholangiocarcinomaversushepatocellularcarcinomaversuscholangiocarcinomaaftersurgicalresectionapropensityscorematchinganalysis
AT liyuchan clinicalfeaturesandoutcomesofcombinedhepatocellularcarcinomaandcholangiocarcinomaversushepatocellularcarcinomaversuscholangiocarcinomaaftersurgicalresectionapropensityscorematchinganalysis
AT wangyachin clinicalfeaturesandoutcomesofcombinedhepatocellularcarcinomaandcholangiocarcinomaversushepatocellularcarcinomaversuscholangiocarcinomaaftersurgicalresectionapropensityscorematchinganalysis
AT shuchihwen clinicalfeaturesandoutcomesofcombinedhepatocellularcarcinomaandcholangiocarcinomaversushepatocellularcarcinomaversuscholangiocarcinomaaftersurgicalresectionapropensityscorematchinganalysis
AT chenyawsen clinicalfeaturesandoutcomesofcombinedhepatocellularcarcinomaandcholangiocarcinomaversushepatocellularcarcinomaversuscholangiocarcinomaaftersurgicalresectionapropensityscorematchinganalysis